Arteriosclerosis, Thrombosis, and Vascular Biology. 1995;15:678-682
© 1995 American Heart Association, Inc.
Articles |
Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
From Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co (J.W.N., H.E.H., D.M.B.), Ann Arbor, Mich; San Diego Endocrine and Medical Clinic (S.R.W.), San Diego, Calif; Chicago Center for Clinical Research (M.H.D.), Chicago, Ill; University of Cincinnati, Lipid Research Clinic (D.L.S.), Cincinnati, Ohio; Diabetes and Glandular Research Clinic (S.L.S.), San Antonio, Tex; Lipid Research Center (P.-J.L.), St Foy, Quebec, Canada; and Baylor College of Medicine (P.H.J.), Houston, Tex.
Abstract This 6-week, double-blind clinical trial evaluated lipid parameter responses to different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor under development. After completing an 8-week placebo-baseline dietary phase, 81 patients were randomly assigned to receive either placebo or 2.5, 5, 10, 20, 40, or 80 mg atorvastatin once daily for 6 weeks. Plasma LDL cholesterol reductions from baseline were dose related, with 25% to 61% reduction from the minimum dose to the maximum dose of 80 mg atorvastatin once a day. Plasma total cholesterol and apo B reductions were also dose related. Previously, reductions in LDL cholesterol of the magnitude observed in this study have been seen only with combination drug therapy. In this study, atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors.
Key Words: atorvastatin • coronary disease • LDL cholesterol • hydroxymethylglutaryl CoA reductase • hypercholesterolemia
This article has been cited by other articles:
 |
|
 |
|
  Y. Alvarez, C. Municio, S. Alonso, J. A. S. Roman, M. S. Crespo, and N. Fernandez Cyclooxygenase-2 Induced by Zymosan in Human Monocyte-Derived Dendritic Cells Shows High Stability, and Its Expression Is Enhanced by Atorvastatin J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 987 - 994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Jacobson, D. A. Wertz, T. Hoy, A. Kuznik, D. Grochulski, and M. Cziraky Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated Mayo Clin. Proc., December 1, 2008; 83(12): 1316 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Ferrer-Garcia, E. Sanchez-Ballester, R. Albalat-Galera, M. Berzosa-Sanchez, and A. Herrera-Ballester Efficacy of Atorvastatin for Achieving Cholesterol Targets After LDL-Cholesterol Based Dose Selection in Patients With Type 2 Diabetes Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 183 - 188. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Lu, H. Xiao, H. You, Y. Lin, H. Jin, B. Snagaski, and C. S. Yang Synergistic Inhibition of Lung Tumorigenesis by a Combination of Green Tea Polyphenols and Atorvastatin Clin. Cancer Res., August 1, 2008; 14(15): 4981 - 4988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S Joy, K. A Dornbrook-Lavender, H. Chin, S. L Hogan, and C. Denu-Ciocca Effects of Atorvastatin on Lp(a) and Lipoprotein Profiles in Hemodialysis Patients Ann. Pharmacother., January 1, 2008; 42(1): 9 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. G. Bone, D. P. Kiel, R. S. Lindsay, E. M. Lewiecki, M. A. Bolognese, E. T. Leary, W. Lowe, and M. R. McClung Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4671 - 4677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Save, N. Patil, N. Moulik, and G. Rajadhyaksha Effect of Atorvastatin on Type 2 Diabetic Dyslipidemia Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 262 - 270. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Abidi, W. Chen, F. B. Kraemer, H. Li, and J. Liu The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms J. Lipid Res., October 1, 2006; 47(10): 2134 - 2147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 762 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Plakogiannis, H. Cohen, and D. Taft Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia Am. J. Health Syst. Pharm., December 1, 2005; 62(23): 2491 - 2494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Ness and K. R. Gertz Hepatic HMG-CoA Reductase Expression and Resistance to Dietary Cholesterol Experimental Biology and Medicine, May 1, 2004; 229(5): 412 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Lins, K. E. Matthys, G. A. Verpooten, P. C. Peeters, M. Dratwa, J.-C. Stolear, and N. H. Lameire Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients Nephrol. Dial. Transplant., May 1, 2003; 18(5): 967 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Nassir, Y. Xie, and N. O. Davidson Apolipoprotein[a] secretion from hepatoma cells is regulated in a size-dependent manner by alterations in disulfide bond formation J. Lipid Res., April 1, 2003; 44(4): 816 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rashid, K. D. Uffelman, P. H. R. Barrett, and G. F. Lewis Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit Circulation, December 3, 2002; 106(23): 2955 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M van Dam, M Zwart, F de Beer, A H M Smelt, M H Prins, M D Trip, L M Havekes, P J Lansberg, and J J P Kastelein Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia Heart, September 1, 2002; 88(3): 234 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shepherd The role of the exogenous pathway in hypercholesterolaemia Eur. Heart J. Suppl., June 1, 2001; 3(suppl_E): E2 - E5. [Abstract] [PDF]
|
|
|
|
 |
|
 J. S. Cohen Dose Discrepancies Between the Physicians' Desk Reference and the Medical Literature, and Their Possible Role in the High Incidence of Dose-Related Adverse Drug Events Arch Intern Med, April 9, 2001; 161(7): 957 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Romero, J. Calvino, J. Rodriguez, and D. Sanchez-Guisande Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins Nephrol. Dial. Transplant., September 1, 2000; 15(9): 1446 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hufnagel, C. Michel, F. Vrtovsnik, G. Queffeulou, N. Kossari, and F. Mignon Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis Nephrol. Dial. Transplant., May 1, 2000; 15(5): 684 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Ness and C. M. Chambers Feedback and Hormonal Regulation of Hepatic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase: The Concept of Cholesterol Buffering Capacity Experimental Biology and Medicine, May 1, 2000; 224(1): 8 - 19. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. C. Hess, A. M. Demchuk, L. M. Brass, and F. M. Yatsu HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention Neurology, February 22, 2000; 54(4): 790 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Farnier, J.-J. Portal, and P. Maigret Efficacy of Atorvastatin Compared With Simvastatin in Patients With Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(1): 27 - 32. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Guerin, T. S. Lassel, W. Le Goff, M. Farnier, and M. J. Chapman Action of Atorvastatin in Combined Hyperlipidemia : Preferential Reduction of Cholesteryl Ester Transfer From HDL to VLDL1 Particles Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 189 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Black, R. N. Hayes, B. D. Roth, P. Woo, and T. F. Woolf Metabolism and Excretion of Atorvastatin in Rats And Dogs Drug Metab. Dispos., August 1, 1999; 27(8): 916 - 923. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.S. Wierzbicki, P.J. Lumb, Y. Semra, G. Chik, E.R. Christ, and M.A. Crook Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias QJM, July 1, 1999; 92(7): 387 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Walsh and C. E. Rothwell Hepatic Effects in Beagle Dogs Administered Atorvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, for 2 Years Toxicol Pathol, July 1, 1999; 27(4): 395 - 401. [Abstract] [PDF]
|
|
|
|
|
|
J. Alfon, T. Royo, X. Garcia-Moll, and L. Badimon Platelet Deposition on Eroded Vessel Walls at a Stenotic Shear Rate Is Inhibited by Lipid-Lowering Treatment With Atorvastatin Arterioscler Thromb Vasc Biol, July 1, 1999; 19(7): 1812 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Burnett, P. H. R. Barrett, P. Vicini, D. B. Miller, D. E. Telford, S. J. Kleinstiver, and M. W. Huff The HMG-CoA Reductase Inhibitor Atorvastatin Increases the Fractional Clearance Rate of Postprandial Triglyceride-Rich Lipoproteins in Miniature Pigs Arterioscler Thromb Vasc Biol, December 1, 1998; 18(12): 1906 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Brown, R. G. Bakker-Arkema, L. Yellen, R. W. Henley Jr., R. Guthrie, C. F. Campbell, M. Koren, W. Woo, R. McLain, and D. M. Black Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin J. Am. Coll. Cardiol., September 1, 1998; 32(3): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Black, M. W. Sinz, R. N. Hayes, and T. F. Woolf Metabolism and Excretion Studies in Mouse After Single and Multiple Oral Doses of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitor Atorvastatin Drug Metab. Dispos., August 1, 1998; 26(8): 755 - 763. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. Black, R. G. Bakker-Arkema, and J. W. Nawrocki An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor Arch Intern Med, March 23, 1998; 158(6): 577 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Ness, C. M. Chambers, and D. Lopez Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity J. Lipid Res., January 1, 1998; 39(1): 75 - 84. [Abstract] [Full Text]
|
|
|
|
|
|
L. Reid, R. Bakker-Arkema, and D. Black The Effect of Atorvastatin on the Human Lens After 52 Weeks of Treatment Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(1): 71 - 76. [Abstract] [PDF]
|
|
|
|
|
|
J. Dallongeville, J.-C. Fruchart, P. Maigret, S. Bertolini, G. Bittolo Bon, M. M. Campbell, M. Farnier, J. Langan, G. Mahla, P. Pauciullo, et al. Double-Blind Comparison of Apolipoprotein and Lipoprotein Particle Lowering Effects of Atorvastatin and Pravastatin Monotherapy in Patients With Primary Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 103 - 110. [Abstract] [PDF]
|
|
|
|
|
|
H. Schrott, A. G. Fereshetian, R. H. Knopp, H. Bays, P. H. Jones, T. W. Littlejohn, R. McLain, and D. M. Black A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 119 - 123. [Abstract] [PDF]
|
|
|
|
|
|
J. R. Burnett, L. J. Wilcox, D. E. Telford, S. J. Kleinstiver, P. H. R. Barrett, R. S. Newton, and M. W. Huff Inhibition of HMG-CoA Reductase by Atorvastatin Decreases Both VLDL and LDL Apolipoprotein B Production in Miniature Pigs Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2589 - 2600. [Abstract] [Full Text]
|
|
|
|
|
|
T. C. Ooi, T. Heinonen, P. Alaupovic, J. Davignon, L. Leiter, P. J. Lupien, A. D. Sniderman, M. H. Tan, G. Tremblay, A. Sorisky, et al. Efficacy and Safety of a New Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, Atorvastatin, in Patients with Combined Hyperlipidemia: Comparison with Fenofibrate Arterioscler Thromb Vasc Biol, September 1, 1997; 17(9): 1793 - 1799. [Abstract] [Full Text]
|
|
|
|
|
|
J. C. LaRosa Triglycerides and Coronary Risk in Women and the Elderly Arch Intern Med, May 12, 1997; 157(9): 961 - 968. [Abstract] [PDF]
|
|
|
|
 |
|
 H. G. Schrott, V. Bittner, E. Vittinghoff, D. M. Herrington, and S. Hulley Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women With Heart Disease: The Heart and Estrogen/Progestin Replacement Study (HERS) JAMA, April 23, 1997; 277(16): 1281 - 1286. [Abstract] [PDF]
|
|
|
|
|
|
E. Stein, D. Sprecher, K.S. Allenby, R.L. Tosiello, E. Whalen, and S.R. Ripa Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 7 - 16. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Isaacsohn, R. G. Bakker-Arkema, R. Fayyad, R. Whitcomb, and D. M. Black Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients with Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 243 - 249. [Abstract] [PDF]
|
|
|
|
|
|
K. M. Walsh, M. A. Albassam, and D. E. Clarke Subchronic Toxicity of Atorvastatin, a Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, in Beagle Dogs Toxicol Pathol, July 1, 1996; 24(4): 468 - 476. [Abstract] [PDF]
|
|
|
|
|
|
T. M. Heinonen, H. Schrott, J. M. McKenney, A. D. Sniderman, F. E. Broyles, J. H. Zavoral, F. Kivel, and D. M. Black Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 117 - 122. [Abstract] [PDF]
|
|
|
|
|
|
R. G. Bakker-Arkema, M. H. Davidson, R. J. Goldstein, J. Davignon, J. L. Isaacsohn, S. R. Weiss, L. M. Keilson, W. V. Brown, V. T. Miller, L. J. Shurzinske, et al. Efficacy and Safety of a New HMG-CoA Reductase Inhibitor, Atorvastatin, in Patients With Hypertriglyceridemia JAMA, January 10, 1996; 275(2): 128 - 133. [Abstract] [PDF]
|
|
|
|
|
|
M. Averna, S. M. Marcovina, D. Noto, T. G. Cole, E. S. Krul, and G. Schonfeld Familial Hypobetalipoproteinemia Is Not Associated With Low Levels of Lipoprotein(a) Arterioscler Thromb Vasc Biol, December 1, 1995; 15(12): 2165 - 2175. [Abstract] [Full Text]
|
|